相关实验视频

Updated: Jan 15, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

阿扎西奥普林或mycophenolate mofetil用于儿科自身免疫细胞衰退:一个倾向性得分匹配的研究

Thomas Pincez¹, Helder Fernandes², Guy Leverger³

¹CEREVANCE, France.

|October 15, 2025

概括

阿扎西奥普林 (AZA) 和菌酸莫菲蒂尔 (MMF) 在治疗儿科自身免疫细胞衰竭 (AIC) 方面表现出类似的有效性和安全性. 然而,AZA可能更适合年长的孩子,而MMF适合年轻的孩子和那些有二次AIC的孩子.

科学领域:

儿科血液学儿科血液学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

对于自身免疫性细胞衰竭 (AIC) 的阿扎西奥普林 (AZA) 和mycophenolate mofetil (MMF) 存在有限的数据.
儿童AIC群体中AZA和MMF没有进行直接比较.

研究的目的:

为了比较AZA与MMF在儿科AIC中的无故障生存期 (FFS).
确定可能从AZA或MMF中获益更多的患者子组.

主要方法:

对预期全国儿科OBS'CEREVANCE队列的分析 (n=343).
使用倾向性得分匹配对AZA和MMF之间的FFS进行比较.
基于诊断时的年龄和AIC类型的子组分析.

主要成果:

总的来说,AZA和MMF表现出可比的FFS (1年FFS:73%,相比76%) 和相似的严重感染率 (约. (每年2%的增长率).
年龄较大 (≥10岁) 与AZA的高FFS有关.
年龄较小 (<10岁) 和二级AIC与货币市场基金的更高FFS有关.

结论:

阿扎西奥普林和mycophenolate mofetil在儿科AIC的整体疗效和安全性方面是可比的.
治疗选择可能以年龄为指导:AZA对于年长的儿童 (≥10岁) 和MMF对于年轻的儿童 (<10岁).
在患有二次性自身免疫性细胞衰竭的患者中,可能更喜欢用mycophenolate mofetil.

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...